바이오스펙테이터

by Sungmin Kim

Samsung Biologics announced on the 18th that it had signed a land sale contract with Incheon Metropolitan City at Incheon City Hall.

This contract is to attract research and manufacturing facilities that can lead the global high-tech pharmaceutical field on 1 lot of industrial facility site (430 Songdo-dong) of the High-tech Industrial Cluster (C) in District 11 of Songdo International City. The agreement was signed by Mayor of Incheon, Jungbok Yoo, the deputy director of the Free Economic Zone Authority, Yong won Sung, and the CEO of Samsung Biologics, John Lim. The site area is 357,366 square meters, and the sale price is 426 billion won.

The Incheon Economic Administration conducted an open recruitment of operators in October of last year and selected Samsung Biologics as the preferred bidder in December of last year; after that, the land sales contract was concluded through a preferential negotiation process.

Samsung Biologics is building the world's largest biopharmaceutical production facility (total of 620,000 liters) based on a single company with the start of construction of its fourth plant last year, 10 years since its establishment, its sales exceed 1.5 trillion won. In addition, the company is continuing its growth momentum by preparing for partial operation of the 4th plant in October.

Through this land purchase, Samsung Biologics aims to build four factories in district 11 to secure additional production facilities beyond the 1st Campus in district 5. Through this, the goal is to establish itself as the world's No. 1 CDMO company, and the total project cost is expected to be around 7 trillion won.

It is also planning to promote an industry promotion project for ventures and small and medium-sized enterprises in the biopharmaceutical field. During the first phase, it is planned to build an industry fostering facility where ventures and SME(small and medium-sized enterprise)s can move in and receive support for R&D and commercialization, and support projects such as consulting/seminar/domestic and overseas networking.

Samsung Biologics expects to create an average of 400 jobs per year through the construction of the 2nd campus in district 11. A total of 4,000 jobs are expected to be created in 2032, 10 years after the signing of the contract, and a total of 10,000 jobs is expected to occur if about 1,000 jobs are created through partner companies and 5,000 construction workers are included.

John Lim, CEO of Samsung Biologics, said, “I would like to express my gratitude to the Ministry of Trade, Industry and Energy and Incheon City for creating the conditions for Samsung Biologics to make preemptive and bold investments. We will become a company that can lead the global biopharmaceutical industry and grow together with the region by implementing the investment plan without any setbacks.”